BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11808341)

  • 1. [Molecular mechanisms on drug transporters in the drug absorption and disposition].
    Masuda S; Inui K
    Nihon Rinsho; 2002 Jan; 60(1):65-73. PubMed ID: 11808341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Transporters involved in hepatobiliary transport of drugs].
    Maeda K
    Nihon Yakurigaku Zasshi; 2010 Feb; 135(2):76-9. PubMed ID: 20154415
    [No Abstract]   [Full Text] [Related]  

  • 3. Blood-brain barrier transporters and response to CNS-active drugs.
    Urquhart BL; Kim RB
    Eur J Clin Pharmacol; 2009 Nov; 65(11):1063-70. PubMed ID: 19727692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular and cell biological analyses for intestinal absorption and renal excretion of drugs].
    Saito H
    Yakugaku Zasshi; 1997 Aug; 117(8):522-41. PubMed ID: 9306727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intestinal drug transporters: in vivo function and clinical importance.
    Kunta JR; Sinko PJ
    Curr Drug Metab; 2004 Feb; 5(1):109-24. PubMed ID: 14965254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal tubular transporters and antiviral drugs: an update.
    Izzedine H; Launay-Vacher V; Deray G
    AIDS; 2005 Mar; 19(5):455-62. PubMed ID: 15764850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular and molecular aspects of drug transport in the kidney.
    Inui KI; Masuda S; Saito H
    Kidney Int; 2000 Sep; 58(3):944-58. PubMed ID: 10972658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biopharmaceutical studies on molecular mechanisms of membrane transport].
    Tsuji A
    Yakugaku Zasshi; 2002 Dec; 122(12):1037-58. PubMed ID: 12510384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4.
    El-Sheikh AA; Greupink R; Wortelboer HM; van den Heuvel JJ; Schreurs M; Koenderink JB; Masereeuw R; Russel FG
    Transl Res; 2013 Dec; 162(6):398-409. PubMed ID: 24036158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal Drug Transporters and Drug Interactions.
    Ivanyuk A; Livio F; Biollaz J; Buclin T
    Clin Pharmacokinet; 2017 Aug; 56(8):825-892. PubMed ID: 28210973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
    Matsushima S; Maeda K; Kondo C; Hirano M; Sasaki M; Suzuki H; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1059-67. PubMed ID: 15901800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of
    Parvez MM; Shin HJ; Jung JA; Shin JG
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223391
    [No Abstract]   [Full Text] [Related]  

  • 14. The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug-drug interactions.
    Tong Z; Yerramilli U; Surapaneni S; Kumar G
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):869-74. PubMed ID: 24627218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine.
    Thwaites DT; Anderson CM
    Exp Physiol; 2007 Jul; 92(4):603-19. PubMed ID: 17468205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Properties of Drugs Interacting with SLC22 Transporters OAT1, OAT3, OCT1, and OCT2: A Machine-Learning Approach.
    Liu HC; Goldenberg A; Chen Y; Lun C; Wu W; Bush KT; Balac N; Rodriguez P; Abagyan R; Nigam SK
    J Pharmacol Exp Ther; 2016 Oct; 359(1):215-29. PubMed ID: 27488918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide transporters: structure, function, regulation and application for drug delivery.
    Terada T; Inui K
    Curr Drug Metab; 2004 Feb; 5(1):85-94. PubMed ID: 14965252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Significant role of transporters in drug hepatobiliary transport].
    Sun J; Sun YB; He ZG
    Yao Xue Xue Bao; 2005 Aug; 40(8):680-5. PubMed ID: 16268499
    [No Abstract]   [Full Text] [Related]  

  • 19. [Role of drug transporters in rational use of drugs 
at high altitude area].
    Li W; Yan B; Wang R; Jia Z
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Mar; 43(3):327-332. PubMed ID: 29701197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized Hepatocyte-Like Cells with Functional Drug Transporters Directly-Reprogrammed from Mouse Fibroblasts and their Potential in Drug Disposition and Toxicology.
    Wu ZT; Yao D; Ji SY; Ni X; Gao YM; Hui LJ; Pan GY
    Cell Physiol Biochem; 2016; 38(5):1815-30. PubMed ID: 27160211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.